628 related articles for article (PubMed ID: 15381240)
1. Therapeutic effects of streptococcal preparation OK-432 on atopic dermatitis-like lesions in NC/Nga mice: possible shift from a Th2- to Th1-predominance.
Horiuchi Y; Bae S; Katayama I; Nishioka K
J Dermatol Sci; 2004 Sep; 35(3):187-97. PubMed ID: 15381240
[TBL] [Abstract][Full Text] [Related]
2. Lipoteichoic acid-related molecule derived from the streptococcal preparation, OK-432, which suppresses atopic dermatitis-like lesions in NC/Nga mice.
Horiuchi Y; Bae S; Katayama I; Oshikawa T; Okamoto M; Sato M
Arch Dermatol Res; 2006 Sep; 298(4):163-73. PubMed ID: 16845523
[TBL] [Abstract][Full Text] [Related]
3. Hyperresponsive TH2 cells with enhanced nuclear factor-kappa B activation induce atopic dermatitis-like skin lesions in Nishiki-nezumi Cinnamon/Nagoya mice.
Tenda Y; Yamashita M; Kimura MY; Hasegawa A; Shimizu C; Kitajima M; Onodera A; Suzuki A; Seki N; Nakayama T
J Allergy Clin Immunol; 2006 Sep; 118(3):725-33. PubMed ID: 16950294
[TBL] [Abstract][Full Text] [Related]
4. Oral administration of Uncariae rhynchophylla inhibits the development of DNFB-induced atopic dermatitis-like skin lesions via IFN-gamma down-regulation in NC/Nga mice.
Kim DY; Jung JA; Kim TH; Seo SW; Jung SK; Park CS
J Ethnopharmacol; 2009 Apr; 122(3):567-72. PubMed ID: 19429328
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effects of combination using glucosamine plus tacrolimus (FK-506) on the development of atopic dermatitis-like skin lesions in NC/Nga mice.
Kim CH; Cheong KA; Park CD; Lee AY
Scand J Immunol; 2012 May; 75(5):471-8. PubMed ID: 22023698
[TBL] [Abstract][Full Text] [Related]
6. Improvement of atopic dermatitis in NC/Nga mice by topical application of CpG phosphodiester-ODN.
Kim YS; Kim Y; Lee KJ; Kwon HJ; Kim DS; Kim TY
Int Arch Allergy Immunol; 2007; 144(4):315-24. PubMed ID: 17671391
[TBL] [Abstract][Full Text] [Related]
7. Oral administration of Yokukansan inhibits the development of atopic dermatitis-like lesions in isolated NC/Nga mice.
Jiang J; Yamaguchi T; Funakushi N; Kuhara T; Fan PS; Ueki R; Suto H; Kase Y; Ikeda S; Ogawa H
J Dermatol Sci; 2009 Oct; 56(1):37-42. PubMed ID: 19647983
[TBL] [Abstract][Full Text] [Related]
8. Topical suplatast tosilate (IPD) ameliorates Th2 cytokine-mediated dermatitis in caspase-1 transgenic mice by downregulating interleukin-4 and interleukin-5.
Murakami T; Yamanaka K; Tokime K; Kurokawa I; Tsutsui H; Nakanishi K; Mizutani H
Br J Dermatol; 2006 Jul; 155(1):27-32. PubMed ID: 16792748
[TBL] [Abstract][Full Text] [Related]
9. Glucosamine improved atopic dermatitis-like skin lesions in NC/Nga mice by inhibition of Th2 cell development.
Kim CH; Cheong KA; Park CD; Lee AY
Scand J Immunol; 2011 Jun; 73(6):536-45. PubMed ID: 21284687
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of Solanum tuberosum L. var. vitelotte extract on 2,4-dinitrochlorobenzene-induced atopic dermatitis in mice.
Shim EH; Choung SY
J Pharm Pharmacol; 2014 Sep; 66(9):1303-16. PubMed ID: 24961480
[TBL] [Abstract][Full Text] [Related]
11. Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization.
Hattori K; Nishikawa M; Watcharanurak K; Ikoma A; Kabashima K; Toyota H; Takahashi Y; Takahashi R; Watanabe Y; Takakura Y
J Immunol; 2010 Mar; 184(5):2729-35. PubMed ID: 20107184
[TBL] [Abstract][Full Text] [Related]
12. CD4+ T cell depletion changes the cytokine environment from a TH1/TH2 response to a TC17-like response in a murine model of atopic dermatitis.
Christensen GB; Hvid M; Kvist PH; Deleuran B; Deleuran M; Vestergaard C; Kemp K
Int Immunopharmacol; 2011 Sep; 11(9):1285-92. PubMed ID: 21530683
[TBL] [Abstract][Full Text] [Related]
13. Topical application of aloperine improves 2,4-dinitrofluorobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice.
Yuan XY; Ma HM; Li RZ; Wang RY; Liu W; Guo JY
Eur J Pharmacol; 2011 May; 658(2-3):263-9. PubMed ID: 21371468
[TBL] [Abstract][Full Text] [Related]
14. Analysis of T cell receptor (TCR) BV-gene clonotypes in NC/Nga mice developing dermatitis resembling human atopic dermatitis.
Matsuoka A; Kato T; Soma Y; Takahama H; Nakamura M; Matsuoka H; Mizoguchi M
J Dermatol Sci; 2005 Apr; 38(1):17-24. PubMed ID: 15795120
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of Baicalein on atopic dermatitis-like skin lesions of NC/Nga mice induced by dermatophagoides pteronyssinus.
Yun MY; Yang JH; Kim DK; Cheong KJ; Song HH; Kim DH; Cheong KJ; Kim YI; Shin SC
Int Immunopharmacol; 2010 Sep; 10(9):1142-8. PubMed ID: 20621172
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic and prophylactic effects of PUVA photochemotherapy on atopic dermatitis-like lesions in NC/Nga mice.
Miyauchi-Hashimoto H; Okamoto H; Sugihara A; Horio T
Photodermatol Photoimmunol Photomed; 2005 Jun; 21(3):125-30. PubMed ID: 15888128
[TBL] [Abstract][Full Text] [Related]
17. Titanium dioxide nanoparticles aggravate atopic dermatitis-like skin lesions in NC/Nga mice.
Yanagisawa R; Takano H; Inoue K; Koike E; Kamachi T; Sadakane K; Ichinose T
Exp Biol Med (Maywood); 2009 Mar; 234(3):314-22. PubMed ID: 19144875
[TBL] [Abstract][Full Text] [Related]
18. Epigallocatechin-3-gallate improves Dermatophagoides pteronissinus extract-induced atopic dermatitis-like skin lesions in NC/Nga mice by suppressing macrophage migration inhibitory factor.
Noh SU; Cho EA; Kim HO; Park YM
Int Immunopharmacol; 2008 Sep; 8(9):1172-82. PubMed ID: 18602062
[TBL] [Abstract][Full Text] [Related]
19. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment.
Yamaguchi Y; Ohshita A; Kawabuchi Y; Hihara J; Miyahara E; Noma K; Toge T
Int J Oncol; 2004 Apr; 24(4):959-66. PubMed ID: 15010836
[TBL] [Abstract][Full Text] [Related]
20. Induction of atopic eczema/dermatitis syndrome-like skin lesions by repeated topical application of a crude extract of Dermatophagoides pteronyssinus in NC/Nga mice.
Kang JS; Lee K; Han SB; Ahn JM; Lee H; Han MH; Yoon YD; Yoon WK; Park SK; Kim HM
Int Immunopharmacol; 2006 Oct; 6(10):1616-22. PubMed ID: 16919834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
